Clinical research status and progress of uveal melanoma in China of 2011-2021
10.3760/cma.j.cn511434-20220131-00062
- VernacularTitle:2011年至2021年中国葡萄膜黑色素瘤研究现状及进展
- Author:
Chuqiao LIANG
1
;
Jingting LUO
;
Yang LI
;
Wenbin WEI
Author Information
1. 首都医科大学附属北京同仁医院 北京同仁眼科中心 眼内肿瘤诊治研究北京市重点实验室 北京市眼科学与视觉科学重点实验室 医学人工智能研究与验证工信部重点实验室, 北京 100730
- Keywords:
Uveal Neoplasms;
Melanoma;
China;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2022;38(3):242-247
- CountryChina
- Language:Chinese
-
Abstract:
Uveal melanoma (UM) is one of the most common primary intraocular malignancy in adults. The incidence of UM is lower in Asia than in Europe and the United States, however, the age of onset of UM patients in Asia is earlier than in the European and American populations. With the improvement of economic living standards in recent years, UM as a rare intraocular tumor has been gradually recognized by the public. In the past 10 years, the research of UM in China has been characterized by a large number and rapid development. Among them, the direction of molecular genetics represented by non-coding RNA, the frontier development of potential anticancer drugs for UM and Chinese traditional medicines are the research hotspots for scholars in China. In the past 10 years, China has made a relatively complete understanding and research progress on the pathogenesis, diagnosis and treatment of UM. On the other hand, compared with European and American countries, China still lacks in frontier research such as immunotherapy. With the further efforts of Chinese ophthalmology researchers and research teams, and with the further development of scientific research in my country, it is believed that the mechanism affecting tumors can be further elucidated, providing more possibilities for treatment and improving the prognosis of UM patients in China.
